Canadian Biotech company Acuitas Therapeutics and Germany-based CureVac NV (NASDAQ:CVAC) have settled Acuitas’ lawsuit over credit for inventions tied to COVID-19 vaccines. In November 2023, Acuitas Therapeutics filed a lawsuit in Virginia federal court against CureVac, accusing it of failing to credit Acuitas on patents related to COVID-19 vaccines. Acuitas told the court that CureVac omitted its scientists from patent applications for lipid nanoparticle technology used in messenger RNA-based vaccines after collaborating to develop the technology during the COVID-19 pandemic. This move would allow Acuitas to license them without CureVac’s consent.  Reuters highlighted that CureVac refuted these claims in a court filing made in February. Acuitas has previously